Cargando…
A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease
BACKGROUND: Parkinson’s disease (PD) is a progressive neurodegenerative condition that primarily affects motor functions; it is caused by the loss of midbrain dopaminergic (mDA) neurons. The therapeutic effects of transplanting human-induced pluripotent stem cell (iPSC)-derived mDA neural progenitor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368972/ https://www.ncbi.nlm.nih.gov/pubmed/37502682 http://dx.doi.org/10.3389/fnins.2023.1202027 |
_version_ | 1785077642837360640 |
---|---|
author | Nakamura, Ryota Nonaka, Risa Oyama, Genko Jo, Takayuki Kamo, Hikaru Nuermaimaiti, Maierdanjiang Akamatsu, Wado Ishikawa, Kei-ichi Hattori, Nobutaka |
author_facet | Nakamura, Ryota Nonaka, Risa Oyama, Genko Jo, Takayuki Kamo, Hikaru Nuermaimaiti, Maierdanjiang Akamatsu, Wado Ishikawa, Kei-ichi Hattori, Nobutaka |
author_sort | Nakamura, Ryota |
collection | PubMed |
description | BACKGROUND: Parkinson’s disease (PD) is a progressive neurodegenerative condition that primarily affects motor functions; it is caused by the loss of midbrain dopaminergic (mDA) neurons. The therapeutic effects of transplanting human-induced pluripotent stem cell (iPSC)-derived mDA neural progenitor cells in animal PD models are known and are being evaluated in an ongoing clinical trial. However, However, improvements in the safety and efficiency of differentiation-inducing methods are crucial for providing a larger scale of cell therapy studies. This study aimed to investigate the usefulness of dopaminergic progenitor cells derived from human iPSCs by our previously reported method, which promotes differentiation and neuronal maturation by treating iPSCs with three inhibitors at the start of induction. METHODS: Healthy subject-derived iPS cells were induced into mDA progenitor cells by the CTraS-mediated method we previously reported, and their proprieties and dopaminergic differentiation efficiency were examined in vitro. Then, the induced mDA progenitors were transplanted into 6-hydroxydopamine-lesioned PD model mice, and their efficacy in improving motor function, cell viability, and differentiation ability in vivo was evaluated for 16 weeks. RESULTS: Approximately ≥80% of cells induced by this method without sorting expressed mDA progenitor markers and differentiated primarily into A9 dopaminergic neurons in vitro. After transplantation in 6-hydroxydopamine-lesioned PD model mice, more than 90% of the engrafted cells differentiated into the lineage of mDA neurons, and approximately 15% developed into mature mDA neurons without tumour formation. The grafted PD model mice also demonstrated significantly improved motor functions. CONCLUSION: This study suggests that the differentiation protocol for the preparation of mDA progenitors is a promising option for cell therapy in patients with PD. |
format | Online Article Text |
id | pubmed-10368972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103689722023-07-27 A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease Nakamura, Ryota Nonaka, Risa Oyama, Genko Jo, Takayuki Kamo, Hikaru Nuermaimaiti, Maierdanjiang Akamatsu, Wado Ishikawa, Kei-ichi Hattori, Nobutaka Front Neurosci Neuroscience BACKGROUND: Parkinson’s disease (PD) is a progressive neurodegenerative condition that primarily affects motor functions; it is caused by the loss of midbrain dopaminergic (mDA) neurons. The therapeutic effects of transplanting human-induced pluripotent stem cell (iPSC)-derived mDA neural progenitor cells in animal PD models are known and are being evaluated in an ongoing clinical trial. However, However, improvements in the safety and efficiency of differentiation-inducing methods are crucial for providing a larger scale of cell therapy studies. This study aimed to investigate the usefulness of dopaminergic progenitor cells derived from human iPSCs by our previously reported method, which promotes differentiation and neuronal maturation by treating iPSCs with three inhibitors at the start of induction. METHODS: Healthy subject-derived iPS cells were induced into mDA progenitor cells by the CTraS-mediated method we previously reported, and their proprieties and dopaminergic differentiation efficiency were examined in vitro. Then, the induced mDA progenitors were transplanted into 6-hydroxydopamine-lesioned PD model mice, and their efficacy in improving motor function, cell viability, and differentiation ability in vivo was evaluated for 16 weeks. RESULTS: Approximately ≥80% of cells induced by this method without sorting expressed mDA progenitor markers and differentiated primarily into A9 dopaminergic neurons in vitro. After transplantation in 6-hydroxydopamine-lesioned PD model mice, more than 90% of the engrafted cells differentiated into the lineage of mDA neurons, and approximately 15% developed into mature mDA neurons without tumour formation. The grafted PD model mice also demonstrated significantly improved motor functions. CONCLUSION: This study suggests that the differentiation protocol for the preparation of mDA progenitors is a promising option for cell therapy in patients with PD. Frontiers Media S.A. 2023-07-12 /pmc/articles/PMC10368972/ /pubmed/37502682 http://dx.doi.org/10.3389/fnins.2023.1202027 Text en Copyright © 2023 Nakamura, Nonaka, Oyama, Jo, Kamo, Nuermaimaiti, Akamatsu, Ishikawa and Hattori. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Nakamura, Ryota Nonaka, Risa Oyama, Genko Jo, Takayuki Kamo, Hikaru Nuermaimaiti, Maierdanjiang Akamatsu, Wado Ishikawa, Kei-ichi Hattori, Nobutaka A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease |
title | A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease |
title_full | A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease |
title_fullStr | A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease |
title_full_unstemmed | A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease |
title_short | A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease |
title_sort | defined method for differentiating human ipscs into midbrain dopaminergic progenitors that safely restore motor deficits in parkinson’s disease |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368972/ https://www.ncbi.nlm.nih.gov/pubmed/37502682 http://dx.doi.org/10.3389/fnins.2023.1202027 |
work_keys_str_mv | AT nakamuraryota adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT nonakarisa adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT oyamagenko adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT jotakayuki adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT kamohikaru adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT nuermaimaitimaierdanjiang adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT akamatsuwado adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT ishikawakeiichi adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT hattorinobutaka adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT nakamuraryota definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT nonakarisa definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT oyamagenko definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT jotakayuki definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT kamohikaru definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT nuermaimaitimaierdanjiang definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT akamatsuwado definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT ishikawakeiichi definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease AT hattorinobutaka definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease |